Interview with the Director, President and CEO: AcelRx Pharmaceuticals, Inc. (ACRX)
Richard King has served as Director, President and Chief Executive Officer of AcelRx Pharmaceuticals, Inc., since May 2010. From April 2009 until May 2010, Mr. King acted as an independent consultant to a number of private and public biotechnology and venture capital companies. From October 2008 to April 2009, Mr. King served as President and General Manager of Tercica, Inc., a biotechnology company that was acquired by Ipsen in 2008; and from February 2008 to October 2008, Mr. King served as President and Chief Operating Officer of Tercica, Inc.; and from February 2007 until February 2008, he served as Chief Operating Officer of Tercica, Inc. From January 2002 to October 2006, Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc., a pharmaceutical company that was acquired by Abbott Laboratories, a global, broad-based health care company, in 2006. From January 2000 to January 2002, Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals, a pharmaceutical company that was acquired by Abbott Laboratories in 2009. From April 1992 to January 2000, Mr. King held various marketing positions at SmithKline Beecham Pharmaceuticals, now known as GlaxoSmithKline, a global pharmaceutical company. Mr. King holds a B.S. in chemical engineering from the University of Surrey and an MBA from Manchester Business School. Profile
TWST: Let's begin with an overview of AcelRx Pharmaceuticals.
Mr. King: AcelRx Pharmaceuticals is a company focused on the management of moderate-to-severe pain, and in